Thomas R. Staab II
2018
Compensation breakdown
| Non-Equity Incentive Plan | $193,157 |
|---|---|
| Option Awards | $1,141,160 |
| Salary | $449,203 |
| Other | $13,750 |
| Total | $1,797,270 |
Staab received $1.1M in option awards, accounting for 63% of the total pay in 2018.
Staab also received $193.2K in non-equity incentive plan, $449.2K in salary and $13.8K in other compensation.
Rankings
In 2018, Thomas R. Staab II's compensation ranked 6,270th out of 14,244 executives tracked by ExecPay. In other words, Staab earned more than 56.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,270 out of 14,244 | 56th |
Division Manufacturing | 2,402 out of 5,765 | 58th |
Major group Chemicals And Allied Products | 898 out of 2,128 | 58th |
Industry group Drugs | 754 out of 1,817 | 59th |
Industry Biological Products, Except Diagnostic Substances | 146 out of 339 | 57th |
Pay ratio
| Thomas R. Staab II's Pay | $1,797,270 |
|---|---|
| Median Employee's Pay | $205,224 |
| Pay Ratio | 9to 1 |
In 2018, the annual total compensation of Thomas R. Staab II was $1,797,270.
The annual total compensation of the median employee at BioCryst Pharmaceuticals was $205,224.
The ratio of Thomas R. Staab II's pay to the pay of median employee was therefore 9 to one.
Staab's colleagues
We found four more compensation records of executives who worked with Thomas R. Staab II at BioCryst Pharmaceuticals in 2018.
2018
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2018
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
2018
Yarlagadda Babu
BioCryst Pharmaceuticals
Senior Vice President of Drug Discovery
2018
Lynne Powell
BioCryst Pharmaceuticals